In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
The triazole antifungal pramiconazole (Stiefel, a GSK company) was compared with itraconazole, miconazole, and terbinafine in vitro and in vivo. Potent in vitro activities against Candida spp. (50% inhibitory concentration [IC₅₀], 0.04 to 1.83 μM) and Microsporum and Trichophyton spp. (IC₅₀, 0.15 to 1.34 μM) were obtained but not, however, against other filamentous molds and zygomycetes. In the M. canis guinea pig model and C. albicans vulvovaginitis rat model, pramiconazole was superior to the reference compounds after oral and topical administration.
de Wit
Kelly
K
Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Groenenborgerlaan 171, Antwerp, Belgium.
Paulussen
Caroline
C
Matheeussen
An
A
van Rossem
Koen
K
Cos
Paul
P
Maes
Louis
L
D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D002176:Candida albicans / Q000472:pathogenicity*; D003872:Dermatitis / Q000382:microbiology*; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020128:Inhibitory Concentration 50; D017964:Itraconazole / Q000493:pharmacokinetics / Q000627:therapeutic use; D008864:Microsporum / Q000472:pathogenicity*; D009281:Naphthalenes / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077291:Terbinafine; D014230:Triazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014627:Vaginitis / Q000382:microbiology*
D000935:Antifungal Agents; D007093:Imidazoles; D009281:Naphthalenes; D014230:Triazoles; D017964:Itraconazole; C482452:pramiconazole; D000077291:Terbinafine
Eur J Clin Microbiol Infect Dis. 2006 Apr;25(4):215-29
16568297
J Ethnopharmacol. 2006 Jul 19;106(3):290-302
16698208
Acta Derm Venereol. 2008;88(5):462-6
18779883
Int J Hyg Environ Health. 2001 Dec;204(4):239-43
11833296
Acta Derm Venereol. 2007;87(1):22-6
17225011
J Med Chem. 2005 Mar 24;48(6):2184-93
15771461
Clin Dermatol. 2010 Mar 4;28(2):197-201
20347663
J Clin Microbiol. 1995 Apr;33(4):915-7
7790460
Antimicrob Agents Chemother. 2004 Jan;48(1):216-23
14693542
Mycopathologia. 2008 Nov-Dec;166(5-6):353-67
18478357
Acta Derm Venereol. 2006;86(4):312-5
16874415
Antimicrob Agents Chemother. 1987 Oct;31(10):1558-61
3435103
Am Fam Physician. 2003 Jan 1;67(1):101-8
12537173
Br J Dermatol. 2007 Jun;156(6):1385-8
17535237
IDrugs. 2008 Sep;11(9):661-70
18763217
Antimicrob Agents Chemother. 2004 Feb;48(2):388-91
14742185
Drugs. 2004;64(18):1997-2020
15341494
Lancet. 2007 Jun 9;369(9577):1961-71
17560449
Br J Dermatol. 2008 Apr;158(4):854-6
18241269
Dermatology. 2007;214(2):162-9
17341867
Curr Drug Targets. 2005 Dec;6(8):849-62
16375669